There was a significant drop-off in NME approvals by FDA in 2016, but there were not enough new drug applications with user fee goals to reach the lofty 2015 total.

Provides identification of potential patient safety issues and actionable insight into clinical trial site performance RESEARCH TRIANGLE PARK, N.C. – June 15, 2015 – Quintiles, the world’s largest biopharmaceutical services company, today announced the addition of advanced statistical monitoring and predictive analytics capabilities to its risk-based monitoring (RBM) solution. Predictive and Advanced Analytics combine Quintiles’ […]